Brenda Spurbeck
Psychiatric/Mental Health · Hogansburg, NYNPI 1629113683
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,825 of the $26,265 with a category attached, or 67.9%. AstraZeneca accounts for 63.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $11,989 and has fallen 98.9% since, to $129 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $107.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Mylan Specialty L.p.$6K
- GSK$1K
- Sanofi$902
- Grifols USA, LLC$257
- Boehringer Ingelheim$234
- plus $1K from 17 others
What the payments were for
- Consulting fees$2,1858%
- Speaking & faculty fees$17,82568%
- Travel & lodging$1,0344%
- Food & beverage$5,13220%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 70 | $16,648 |
| Mylan Specialty L.p. | 19 | $5,557 |
| GSK | 72 | $1,402 |
| Sanofi | 8 | $902 |
| Grifols USA, LLC | 13 | $257 |
| Boehringer Ingelheim | 12 | $234 |
| Electromed, Inc. | 16 | $227 |
| Braeburn Inc. | 1 | $115 |
| Advanced Respiratory, Inc | 5 | $102 |
| Axsome Therapeutics, Inc. | 1 | $101 |
| Philips North America LLC | 6 | $101 |
| Alkermes, Inc. | 3 | $80 |
| Regeneron Healthcare Solutions, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 1 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $66 |
| Neurocrine Biosciences, Inc. | 1 | $63 |
| Sanofi-aventis U.S. LLC | 1 | $59 |
| Amgen | 3 | $58 |
| Insmed, Inc. | 3 | $51 |
| Pulmonx Corporation | 1 | $31 |
| Baxter Healthcare | 1 | $27 |
| Pharming Healthcare, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,265 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 455 | $347,404 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 153 | $119,833 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 180 | $114,489 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 113 | $72,782 |
| Dupixent PenDupilumab | 17 | $62,844 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 72 | $41,634 |
| Incruse ElliptaUmeclidinium Bromide | 79 | $38,390 |
| NucalaMepolizumab | 11 | $36,637 |
| Spiriva RespimatTiotropium Bromide | 49 | $33,170 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 55 | $31,755 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 217 | $8,951 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,652 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $6,213 |
| Arnuity ElliptaFluticasone Furoate | 16 | $5,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Nucala, Breo Ellipta | $1,402 | $556,968769 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $16,648 | $159,239236 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $234 | $147,587234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Hogansburg
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
- Vera ImperialeAlbany$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.